# EDGAR Filing Document

**Accession Number:** 0001789972
**File Stem:** 0000000000-23-002325
**Filing Date:** 2023-3
**Character Count:** 2610
**Document Hash:** 9cff12df644e7399994b57d6a9548574
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002325.hdr.sgml**: 20230616

**ACCESSION NUMBER**: 0000000000-23-002325

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230309

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cullinan Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001789972
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 813867811
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** ONE MAIN STREET
- **STREET 2:** SUITE 1350
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-410-4650

**MAIL ADDRESS:**
- **STREET 1:** ONE MAIN STREET
- **STREET 2:** SUITE 1350
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cullinan Management, Inc.
- **DATE OF NAME CHANGE:** 20210107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cullinan Oncology, LLC
- **DATE OF NAME CHANGE:** 20191001
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-23-065343

## Text-Extract

```

United States securities and exchange commission logo

                        March 9, 2023

       Jeff Trigilio
       Chief Financial Officer
       Cullinan Oncology, Inc.
       One Main Street, Suite 1350
       Cambridge, MA 02142

                                                        Re: Cullinan Oncology,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed March 9, 2023
                                                            File No. 333-270384

       Dear Jeff Trigilio:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jimmy
McNamara at 202-551-7349 with any questions.

                        Sincerely,

                        Division of Corporation Finance

                        Office of Life Sciences
       cc:                                              Thomas J. Danielski

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._